<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id><journal-id journal-id-type="publisher-id">JCMM</journal-id><journal-title-group><journal-title>Journal of Cellular and Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1582-1838</issn><issn pub-type="epub">1582-4934</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7264656</article-id><article-id pub-id-type="doi">10.1111/jcmm.15364</article-id><article-id pub-id-type="publisher-id">JCMM15364</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Scientific research progress of COVID&#x02010;19/SARS&#x02010;CoV&#x02010;2 in the first five months</article-title><alt-title alt-title-type="left-running-head">LI et al.</alt-title></title-group><contrib-group><contrib id="jcmm15364-cr-0001" contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Hua</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9644-6768</contrib-id><xref ref-type="aff" rid="jcmm15364-aff-0001">
<sup>1</sup>
</xref><address><email>lihua199988@hotmail.com</email></address></contrib><contrib id="jcmm15364-cr-0002" contrib-type="author"><name><surname>Liu</surname><given-names>Zhe</given-names></name><xref ref-type="aff" rid="jcmm15364-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcmm15364-cr-0003" contrib-type="author" corresp="yes"><name><surname>Ge</surname><given-names>Junbo</given-names></name><xref ref-type="aff" rid="jcmm15364-aff-0001">
<sup>1</sup>
</xref><address><email>ge.junbo@zs-hospital.sh.cn</email></address></contrib></contrib-group><aff id="jcmm15364-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<named-content content-type="organisation-division">Shanghai Institute of Cardiovascular Diseases</named-content>
<named-content content-type="organisation-division">Shanghai Xuhui District Central Hospital and Zhongshan&#x02010;Xuhui Hospital</named-content>
<named-content content-type="organisation-division">Zhongshan Hospital</named-content>
<institution>Fudan University</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="jcmm15364-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>BestNovo (Beijing) Medical Technology Co., Ltd</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hua Li and Junbo Ge, Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Shanghai Xuhui District Central Hospital &#x00026; Zhongshan&#x02010;xuhui Hospital, Zhongshan Hospital, Fudan University, 179 Fenglin Road, Shanghai, 200032, China.<break/>
Emails: <email>lihua199988@hotmail.com</email>; <email>ge.junbo@zs-hospital.sh.cn</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><volume>24</volume><issue>12</issue><issue-id pub-id-type="doi">10.1111/jcmm.v24.12</issue-id><fpage>6558</fpage><lpage>6570</lpage><history><date date-type="received"><day>15</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The Authors. <italic>Journal of Cellular and Molecular Medicine</italic> published by Foundation for Cellular and Molecular Medicine and John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JCMM-24-6558.pdf"/><abstract id="jcmm15364-abs-0001"><title>Abstract</title><p>A cluster of pneumonia (COVID&#x02010;19) cases have been found in Wuhan China in late December, 2019, and subsequently, a novel coronavirus with a positive stranded RNA was identified to be the aetiological virus (severe acute respiratory syndrome coronavirus 2, SARS&#x02010;CoV&#x02010;2), which has a phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS&#x02010;CoV). SARS&#x02010;CoV&#x02010;2 transmits mainly through droplets and close contact and the elder or people with chronic diseases are high&#x02010;risk population. People affected by SARS&#x02010;CoV&#x02010;2 can be asymptomatic, which brings about more difficulties to control the transmission. COVID&#x02010;19 has become pandemic rapidly after onset, and so far the infected people have been above 2&#x000a0;000&#x000a0;000 and more than 130&#x000a0;000 died worldwide according to COVID&#x02010;19 situation dashboard of World Health Organization (<ext-link ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link>). Here, we summarized the current known knowledge regarding epidemiological, pathogenesis, pathology, clinical features, comorbidities and treatment of COVID&#x02010;19/ SARS&#x02010;CoV&#x02010;2 as reference for the prevention and control COVID&#x02010;19.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Natural Science Foundation of China </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>81521001, 81870182</award-id></award-group><award-group id="funding-0002"><funding-source>National Key Basic Research Programme</funding-source><award-id>2016YFC1301204, 2020YFC1316701</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="13"/><word-count count="10364"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.4 mode:remove_FC converted:17.06.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcmm15364-cit-1001">
<string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>J</given-names>
</string-name>. <article-title>Scientific research progress of COVID&#x02010;19/SARS&#x02010;CoV&#x02010;2 in the first five months</article-title>. <source xml:lang="en">J Cell Mol Med</source>. <year>2020</year>;<volume>24</volume>:<fpage>6558</fpage>&#x02013;<lpage>6570</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15364</pub-id>
</mixed-citation>
</p></notes></front><body id="jcmm15364-body-0001"><sec sec-type="background" id="jcmm15364-sec-0001"><label>1</label><title>BACKGROUND</title><p>In late December 2019, a cluster of pneumonia (COVID&#x02010;19) cases with unidentified causes have been found in Wuhan, Hubei Province, China. It is related to a positive stranded RNA virus (severe acute respiratory syndrome coronavirus 2, SARS&#x02010;CoV&#x02010;2), which has a phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS&#x02010;CoV).<xref rid="jcmm15364-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> From the beginning, COVID&#x02010;19 was reported to be epidemiologically linked to the Huanan Seafood Wholesale Market, where there was sale of local fish and live wild animals.<xref rid="jcmm15364-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> The subsequent evidence of clinician infection suggests that SARS&#x02010;CoV&#x02010;2 can transmit from human to human.<xref rid="jcmm15364-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> Massive alveolar damage and progressive respiratory failure may lead to death in severe cases, and the counts of lymphocyte, monocyte, leucocyte, infection&#x02010;related biomarkers, inflammatory cytokines and T cells are also changed in severe patients.<xref rid="jcmm15364-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="jcmm15364-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>
</p><p>Many diagnosis and treatment strategies have been taken to prevent the spread of SARS&#x02010;CoV&#x02010;2 and isolation is the most effective way. Detection of SARS&#x02010;CoV&#x02010;2 nucleic acid or specific IgM and IgG in serum has become a convenient way to identify COVID&#x02010;19. For hospitalized patients, drug treatment such as alpha interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate and arbidol, and convalescent plasma therapy may be potential options. Convalescent plasma therapy is mainly used for the severe and critical cases. In this article, we aim to describe the epidemiological, pathogenesis, pathology, clinical features, comorbidities and treatment of COVID&#x02010;19/SARS&#x02010;CoV&#x02010;2.</p></sec><sec id="jcmm15364-sec-0002"><label>2</label><title>EPIDEMIOLOGY</title><p>So far, the COVID&#x02010;19 patients of nine countries have surpassed 50&#x000a0;000 and they are American, Spain, Italy, Germany, France, The United Kingdom, China, Iran and Turkey in a descending order. The number of confirmed cases and deaths of COVID&#x02010;19 was higher than SARS&#x02010;CoV (more than 8000 confirmed cases and 800 deaths worldwide) and MERS&#x02010;CoV (2494 confirmed cases and 858 deaths worldwide).<xref rid="jcmm15364-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> In a study of 99 COVID&#x02010;19 cases, nearly half of patients (49) were clustered and had exposure history.<xref rid="jcmm15364-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> According to a survey conducted by Chinese Centers for Disease Control and Prevention on more than 40,000 COVID&#x02010;19 patients, about 56% of the patients were men and the median age was 59&#x000a0;years with 87% 30&#x02010;79&#x000a0;years of age, 3% 80&#x000a0;years or older and 2% under 20&#x000a0;years old.<xref rid="jcmm15364-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="jcmm15364-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> The overall case fatality rate (CFR) was 2.3%, in which the CFR of the elderly and patients with pre&#x02010;existing comorbid conditions was higher. The CFR of over 70&#x02010;year&#x02010;old and over 80&#x02010;year&#x02010;old (including 80&#x000a0;years old) was around 50.8% and 14.8% of the total number of deaths, respectively. No deaths occurred in the group aged 9&#x000a0;years and younger.<xref rid="jcmm15364-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> The incubation period of COVID&#x02010;19 was 1&#x02010;14&#x000a0;days with mostly 3&#x02010;7&#x000a0;days, and the maximum incubation period could reach 24&#x000a0;days.<xref rid="jcmm15364-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> A recent study constructed a model&#x02010;based analysis estimating the severity of COVID&#x02010;19 from the cases of 38 countries. The results showed that the mean duration from onset of symptoms to death and hospital discharge was 17.8&#x000a0;days (95% CI, 16.9&#x02010;19.2) and 24.7&#x000a0;days (22.9&#x02010;28.1), respectively. The case fatality ratio in China was 1.38% (1.23&#x02010;1.53), with substantially higher ratios in older age groups (6.4% [5.7&#x02010;7.2], &#x02265;60&#x000a0;years) and up to 13.4% (11.2&#x02010;15.9) in those aged 80&#x000a0;years or older. Estimates of case fatality ratio from international cases stratified by age were consistent with those from China (4.5% [1.8&#x02010;11.1] in those aged &#x02265;60&#x000a0;years [n&#x000a0;=&#x000a0;151]).<xref rid="jcmm15364-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><p>SARS&#x02010;CoV&#x02010;2 has strong transmission ability, and it has been occurred human&#x02010;to&#x02010;human transmission. The basic reproductive number (R<sub>0</sub>) of SARS&#x02010;CoV&#x02010;2 was estimated ~2.2 based on early patients and a subsequent study based on 75&#x000a0;815 individuals (from 31 December 2019 to 28 January 2020) estimated that R<sub>0</sub> was 2.68.<xref rid="jcmm15364-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="jcmm15364-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Recent study from the Los Alamos National Laboratory has collected extensive individual case reports and designed mathematical modelling, which calculated the median R<sub>0</sub> value as 5.7 (95% CI 3.8&#x02010;8.9).<xref rid="jcmm15364-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Therefore, the R<sub>0</sub> of SARS&#x02010;CoV&#x02010;2 is rising with the increased number of confirmed cases and so far it has exceeded the R<sub>0</sub> of MERS (R<sub>0</sub>&#x000a0;=&#x000a0;0.6) and SARS (R<sub>0</sub>&#x000a0;=&#x000a0;1).<xref rid="jcmm15364-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> Scientists have predicted the trend of COVID&#x02010;19 development by studying its epidemic dynamics. It was indicated that Wuhan epidemic would peak around April 2020 and local epidemic across cities in mainland China would lag by 1&#x02010;2&#x000a0;weeks in a study.<xref rid="jcmm15364-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> In another study, researchers estimated the epidemic peak would be on 17 February 2020 in China and an obvious rise could occur from 25 to 29 February 2020 overseas.<xref rid="jcmm15364-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> Asymptomatic cases with COVID&#x02010;19 accounted for ~1% of the total number of patients and the viral load of asymptomatic patients was similar to that of symptomatic patients, which indicated that asymptomatic patients also had the potential to transmit virus.<xref rid="jcmm15364-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="jcmm15364-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> SARS&#x02010;CoV&#x02010;2 is mainly transmitted by droplets, which invade the human body through contaminating the human conjunctival epithelium such as nose and eyes and cause infection.<xref rid="jcmm15364-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> In addition to droplet transmission, faecal&#x02010;oral spread is also a potential mode of transmission.<xref rid="jcmm15364-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> Although no studies have found COVID&#x02010;19 in newborns, specific antibodies have been detected in some newborns,<xref rid="jcmm15364-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="jcmm15364-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> which indicated the possibility of transmission from the mother to her baby. Due to the particularity of droplet transmission, close contact activities, such as family clustering, usually increase the possibility of infection.<xref rid="jcmm15364-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="jcmm15364-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> To block the viral transmission by isolation, wearing masks and other ways of reducing close contact are recommended.</p></sec><sec id="jcmm15364-sec-0003"><label>3</label><title>PATHOGENESIS</title><sec id="jcmm15364-sec-0004"><label>3.1</label><title>Viral genome information and viral origin</title><p>Since COVID&#x02010;19 outbreak, the novel coronavirus SARS&#x02010;CoV&#x02010;2 causing the epidemic has been sequenced by worldwide scholars especially in China. A total of 9556 SARS&#x02010;CoV&#x02010;2 genome sequences have been uploaded in various global databases according to the data of the China National Center for Bioinformation 2019 Novel Coronavirus Resource (2019&#x02010;nCoVR) (Figure&#x000a0;<xref rid="jcmm15364-fig-0001" ref-type="fig">1</xref>). Disclosure of the genome and amino acid sequence will contribute greatly to the viral classification and traceability, rapid nucleic acid detection of patients and understanding of the mechanism of viral infection and transmission. Especially, the clear viral sequence data could directly guide the selection of therapeutic agents and lay the foundation for subsequent vaccine and drug research and development.</p><fig fig-type="Figure" xml:lang="en" id="jcmm15364-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The distribution of virus submitted by different regions. In the world, China, United Kingdom and United States have uploaded 569, 3521 and 2022 virus sequences, respectively</p></caption><graphic id="nlm-graphic-1" xlink:href="JCMM-24-6558-g001"/></fig><p>SARS&#x02010;CoV&#x02010;2 is composed of at least 11 ORFs (Open Reading Frames) with the full length of 29&#x000a0;903 bp.<xref rid="jcmm15364-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> Its genome is similar to SARS&#x02010;CoV with a gene order 5'&#x02010;ORF1ab&#x02010;S&#x02010;E&#x02010;M&#x02010;N&#x02010;3'. A large gene encoding a replicase (ORF1ab) is followed by 4 major structural protein&#x02010;coding genes: S (Spike protein), E (Envelope protein), M (Membrane protein) and N (Nucleocapsid protein). There are also at least 6 accessory ORFs.<xref rid="jcmm15364-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>, <xref rid="jcmm15364-bib-0022" ref-type="ref">
<sup>22</sup>
</xref> SARS&#x02010;CoV&#x02010;2 belongs to the &#x003b2; coronavirus and its sequence significantly differs from that of SARS&#x02010;CoV and MERS&#x02010;CoV, which have caused epidemics previously.<xref rid="jcmm15364-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> Sequence alignment displays that SARS&#x02010;CoV&#x02010;2 has 79% and 50% identity with SARS&#x02010;CoV and MERS&#x02010;CoV, respectively,<xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> whereas 96.3% identity with a bat's coronavirus.<xref rid="jcmm15364-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> Phylogenetic analysis suggests that the closest relatives of SARS&#x02010;CoV&#x02010;2 are several viruses originated from bats, such as Bat&#x02010;CoV RaTG3, Bat SARSr CoV&#x02010;ZC45 and Bat SARSr CoV&#x02010;ZXC21. Therefore, bats are assumed to be the original host of SARS&#x02010;CoV&#x02010;2. However, there should be an intermediate host, who transfers the novel coronavirus to human because the sequence of SARS&#x02010;CoV&#x02010;2 and bat virus Bat&#x02010;CoV RaTG3 has minor difference.<xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="jcmm15364-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> The suspicious intermediate host has been suggested to be the pangolin by Chinese scientists on the basis of genetic analyses, which has not been confirmed until now with the release of new pangolin coronavirus genome studies.<xref rid="jcmm15364-bib-0026" ref-type="ref">
<sup>26</sup>
</xref> A recent study has found that the SARS&#x02010;COV&#x02010;2 was easy to infect cats and ferrets, but weakly infectious to dogs, pigs, chickens and ducks, which could be important for the traceability of the SARS&#x02010;COV&#x02010;2.<xref rid="jcmm15364-bib-0027" ref-type="ref">
<sup>27</sup>
</xref> Multiple sequence analysis studies have shown that the genome sequences of SARS&#x02010;CoV&#x02010;2 exhibit more than 99% sequence identity.<xref rid="jcmm15364-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="jcmm15364-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> As a typical RNA virus, the average substitution rate for coronavirus is 10<sup>&#x02212;4</sup> substitutions per year per site.<xref rid="jcmm15364-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> The low heterogeneity among sequences suggests that all these SARS&#x02010;CoV&#x02010;2 originated from the same ancestor within a very short period.<xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> Despite the low heterogeneity, the number of viral genome variants will consistently increase with the continuous spread of COVID&#x02010;19. So far, 4007 variants have been identified and include single nucleotide polymorphism (SNP), deletion, indel and insertion with the mutant numbers of 3951, 82, 10 and 20, respectively (<ext-link ext-link-type="uri" xlink:href="https://bigd.big.ac.cn/ncov">https://bigd.big.ac.cn/ncov</ext-link>). A deletion of eight amino acid has been reported in viral polyprotein 1ab (pp1ab) protein, encoded by ORF1ab gene of SARS&#x02010;CoV&#x02010;2. The pp1ab protein is composed of 16 mature non&#x02010;structural proteins (NSPs) and seldom reported to have mutations previously. This mutant was isolated from a Japanese COVID&#x02010;19 patient, who did not show critical symptoms.<xref rid="jcmm15364-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> Domenico group described the presence of two mutations of SARS&#x02010;CoV&#x02010;2, affecting the NSP6 (amino acid position 3691) and ORF10 adjacent regions (amino acid position 9659), respectively, and both mutations could confer lower stability of the protein structures.<xref rid="jcmm15364-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> Another two mutations of nt28144 in ORF8 and nt8782 in ORF1a of SARS&#x02010;CoV&#x02010;2 have been noticed to have higher mutation rate of 30.53% and 29.47%, respectively.<xref rid="jcmm15364-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> A study analysed 103 SARS&#x02010;CoV&#x02010;2 genomes and also found nt28144 mutant in ORF8. They classified the SARS&#x02010;CoV&#x02010;2 virus as type L (28144T) and S (28144C) based on the different amino acid of leucine and serine in nt28144. S type was indicated to be the ancestral version although the L type (mutation rate ~70%) was more prevalent than the S type (mutation rate ~30%).<xref rid="jcmm15364-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> L type was speculated to be more aggressive and contagious. By analysis of 160 complete human SARS&#x02010;CoV&#x02010;2 genomes, researchers from the University of Cambridge found three central variants distinguished by amino acid alteration, named A (8782T, 28144C), B (derived from A, 8782C, 28144T) and C (derived from B, 26144T), with A being the ancestral type according to the bat out&#x02010;group coronavirus.<xref rid="jcmm15364-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> The A and C types were found mainly in Europeans and Americans, whereas the B type was the most common type in East Asia.</p><p>Currently, the reported mutation rate of SARS&#x02010;CoV&#x02010;2 is generally low and there is no evidence that viral recombination has occurred. Moreover, many countries have not published relevant virus genome information or only a small amount of genome information, which is obviously difficult to truly reflect the full picture of the SARS&#x02010;CoV&#x02010;2 mutation. Consequently, whether the variants of SARS&#x02010;CoV&#x02010;2 could affect its reproduction and transmission need further studies to clarify.</p><p>Recently, researchers have reported that they have successfully cloned and resurrected the novel coronaviruses using reverse genetics,&#x000a0;a method of synthesizing viruses by cloning a known viral genome sequence. This method can provide researchers with infectious virus strains without valuable clinical samples and is an attractive alternative to obtain infectious virus strains.<xref rid="jcmm15364-bib-0034" ref-type="ref">
<sup>34</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0005"><label>3.2</label><title>The receptor of SARS&#x02010;CoV&#x02010;2: Angiotensin converting enzyme II (ACE2)</title><p>The envelope spike (S) protein is crucial for determining host tropism and transmission capacity.<xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> Although the sequence identity of SARS&#x02010;CoV&#x02010;2 and SARS&#x02010;CoV is only 79%, their spike proteins have a highly similar three&#x02010;dimensional structure in the receptor&#x02010;binding domain (RBD),<xref rid="jcmm15364-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>, <xref rid="jcmm15364-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> which makes it possible that SARS&#x02010;CoV&#x02010;2, like SARS&#x02010;CoV, invades cells through the receptor ACE2. Viral infectivity studies using HeLa cells with and without ACE2 expression from humans, Chinese horseshoe bats, civets, pigs and mice reveal that SARS&#x02010;CoV&#x02010;2 is able to use all ACE2 except that of mouse as an entry receptor.<xref rid="jcmm15364-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> To further understand the interaction of SARS&#x02010;CoV&#x02010;2 and ACE2 receptor, scientists from the United States and China separately analysed the cryo&#x02010;electronic microscope (cryo&#x02010;EM) structures of SARS&#x02010;CoV&#x02010;2 S protein<xref rid="jcmm15364-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> and ACE2 receptor, as well as the three&#x02010;dimensional structure of S protein RBD and the full&#x02010;length protein complex of ACE2 receptor.<xref rid="jcmm15364-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> Molecular modelling reveals that SARS&#x02010;CoV&#x02010;2 RBD interacts more strongly with ACE2 receptor than that of SARS&#x02010;CoV.<xref rid="jcmm15364-bib-0035" ref-type="ref">
<sup>35</sup>
</xref> Surface plasmon resonance analysis reveals that the affinity of human ACE2 protein binding to the novel coronavirus S protein is 10&#x02010; to 20&#x02010;fold higher than that of ACE2 binding to SARS&#x02010;CoV S protein, which results in a stronger SARS&#x02010;CoV&#x02010;2 transmission capacity.<xref rid="jcmm15364-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> These evidences strongly support that SARS&#x02010;CoV&#x02010;2 infects host cells by binding ACE2 receptor.</p><p>ACE2 belongs to a type I membrane protein expressed highly in lungs, oesophagus upper and stratified epithelial cells, intestine, absorptive enterocytes from ileum and colon, cholangiocytes, myocardial cells, kidney proximal tubule cells and testicle, which will be preferentially attacked.<xref rid="jcmm15364-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="jcmm15364-bib-0040" ref-type="ref">
<sup>40</sup>
</xref>, <xref rid="jcmm15364-bib-0041" ref-type="ref">
<sup>41</sup>
</xref> COVID&#x02010;19 transmission through faecal&#x02010;oral has been proved by evidences that diarrhoea and other alimentary system symptoms are the main manifestations of some patients<xref rid="jcmm15364-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> and the stool samples of patients with diarrhoea are positive for SARS&#x02010;CoV&#x02010;2 nucleic acid test.<xref rid="jcmm15364-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> The renal and testicle, highly expressing ACE2, may be potential to be invaded by SARS&#x02010;CoV&#x02010;2.<xref rid="jcmm15364-bib-0043" ref-type="ref">
<sup>43</sup>
</xref>
</p><p>The interaction between viral S protein and cell surface receptor ACE2 could activate the downstream renin&#x02010;angiotensin&#x02010;aldosterone system (RAAS) since ACE2 is one of the crucial components of RAAS (Figure&#x000a0;<xref rid="jcmm15364-fig-0002" ref-type="fig">2</xref>). RAAS could be involved in the COVID&#x02010;19 pathogenesis and could balance the RAAS by increasing ACE2 or blocking the interaction between AngII, and AT1/AT2 could be a potential therapeutic target for COVID&#x02010;19.<xref rid="jcmm15364-bib-0044" ref-type="ref">
<sup>44</sup>
</xref>
</p><fig fig-type="Figure" xml:lang="en" id="jcmm15364-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The mechanism of SARS&#x02010;CoV&#x02010;2 and ACE2 interaction based on renin&#x02010;angiotensin&#x02010;aldosterone system (RAAS) and potential therapeutic strategies in COVID&#x02010;19. SARS&#x02010;CoV&#x02010;2 invades cells via ACE2 receptor, which may lead to the down&#x02010;regulation of ACE2 expression. The down&#x02010;regulation of ACE2 expression could destroy the balance between ACE/ACE2 and lead to the tissue injury. Potential therapeutic approaches include a SARS&#x02010;CoV&#x02010;2 spike protein&#x02010;based vaccine and small&#x02010;molecule inhibitors to block the interaction between S protein and ACE2</p></caption><graphic id="nlm-graphic-3" xlink:href="JCMM-24-6558-g002"/></fig></sec><sec id="jcmm15364-sec-0006"><label>3.3</label><title>Cytokine storm</title><p>It was found that before death, the level of neutrophil count, D&#x02010;dimer, blood urea and creatinine levels of COVID&#x02010;19 patients continued to increase and the lymphocyte counts continued to decrease. These changes were related to cytokine storm, suggesting the activation of coagulation system, continuous inflammatory response and the occurrence of acute kidney injury, which could be involved into the pathogenesis of COVID&#x02010;19 exacerbation and explain the death of COVID&#x02010;19 patients.<xref rid="jcmm15364-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>
</p></sec></sec><sec id="jcmm15364-sec-0007"><label>4</label><title>PATHOLOGY</title><p>Although greatly resembled pathological features of COVID&#x02010;19 with SARS and MERS coronavirus infection, COVID&#x02010;19 patients were found to have the unique pathological feature presenting as bilateral diffuse alveolar damage with cellular fibromyxoid exudates. Interstitial mononuclear inflammatory infiltrates dominated by lymphocytes were seen in both lungs, and multinucleated syncytial cells with atypical enlarged pneumocytes characterized by large nuclei, amphophilic granular cytoplasm and prominent nucleoli were identified in the intra&#x02010;alveolar spaces, showing viral cytopathic&#x02010;like changes.<xref rid="jcmm15364-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0008"><label>5</label><title>CLINICAL FEATURES</title><p>COVID&#x02010;19 is characterized by fever, weakness, dry cough, muscle soreness and dyspnoea. According to the study based on 1099 COVID&#x02010;19 hospitalized patients (926 non&#x02010;severe patients and 173 severe patients), fever was the most common symptom with 88.7% patients, followed by cough (67.8%), nausea or vomiting accounted for 5% of the total, 3.8% of the patients with diarrhoea and some patients with dizziness. Meanwhile, about 23.7% of the patients had hypertension or other underlying comorbidities.<xref rid="jcmm15364-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>, <xref rid="jcmm15364-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> A survey of 138 COVID&#x02010;19 hospitalized patients indicated that a considerable cases had comorbidities with 31.2% (43) hypertension, 10.1% (14) diabetes, 14.5% (20) cardiovascular disease and 7.2% (10) malignant.<xref rid="jcmm15364-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>
</p><p>There are many COVID&#x02010;19 risk factors, and age, gender and blood type seem to be more important among them. In a retrospective, multicentre cohort study, older age is significantly correlated with COVID&#x02010;19, which is consistent with the higher incidence of older people. High Sequential Organ Failure Assessment (SOFA) score and D&#x02010;dimer &#x0003e;1&#x000a0;&#x003bc;g/L are also risk factors.<xref rid="jcmm15364-bib-0047" ref-type="ref">
<sup>47</sup>
</xref> Gender is another risk factor, and a lot of research have disclosed that higher prevalence of COVID&#x02010;19 in men than women.<xref rid="jcmm15364-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> It may be related to sex&#x02010;based immunological or behavioural difference, such as smoking and so on.<xref rid="jcmm15364-bib-0049" ref-type="ref">
<sup>49</sup>
</xref> According to a research based on large population, A and O blood group displayed different association risks for COVID&#x02010;19. COVID&#x02010;19 patients with blood group A account for 37.75%, whereas the proportion is 32.16% in normal people. Respectively, the proportion of O group in COVID&#x02010;19 patients and normal people is 25.80% and 33.84%.<xref rid="jcmm15364-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> This result is similar to the study focused on the relationship between ABO blood group and SARS&#x02010;CoV, which showed O blood group with a lower infection chance and anti&#x02010;A antibodies specifically inhibit the adhesion of SARS&#x02010;CoV S protein&#x02010;expressing cells to ACE2&#x02010;expressing cell lines.<xref rid="jcmm15364-bib-0051" ref-type="ref">
<sup>51</sup>
</xref>, <xref rid="jcmm15364-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> These studies may contribute to the therapeutic strategy design of COVID&#x02010;19, but further studies need to be done to clarify the detailed mechanism.</p><p>In the early stage of COVID&#x02010;19, the total number of peripheral blood leucocytes was normal or decreased and the lymphocyte count was decreased. In some patients, liver enzyme, lactate dehydrogenase (LDH), muscle enzyme, aspartate transaminase level and myoglobin were increased.<xref rid="jcmm15364-bib-0053" ref-type="ref">
<sup>53</sup>
</xref> The numbers of helper T cells, suppressor T cells and regulatory T cells were significantly reduced in patients of severe COVID&#x02010;19, whereas the percentage of na&#x000ef;ve T cells increased.<xref rid="jcmm15364-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Pneumonia is the typical symptom of COVID&#x02010;19, and the character of pulmonary image from high&#x02010;resolution computed tomography (HRCT) includes multiple small patchy shadows, interstitial changes, multiple ground glass opacities and infiltration in both lungs and so on.<xref rid="jcmm15364-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>, <xref rid="jcmm15364-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> In severe cases, pulmonary consolidation may occur whereas pleural effusion is rare.<xref rid="jcmm15364-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>, <xref rid="jcmm15364-bib-0055" ref-type="ref">
<sup>55</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0009"><label>6</label><title>COVID&#x02010;19 AND COMPLICATIONS</title><sec id="jcmm15364-sec-0010"><label>6.1</label><title>COVID&#x02010;19 and cardiovascular system</title><p>A study of 41 patients diagnosed with COVID&#x02010;19 showed that hypersensitive troponin I (hs&#x02010;cTnI) was increased substantially in five patients with the diagnosis of virus&#x02010;related cardiac injury. Four out of the five patients were admitted to the ICU, accounting for 31% of the total ICU patients.<xref rid="jcmm15364-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> In a study of 138 COVID&#x02010;19 patients admitted to Zhongnan Hospital of Wuhan University, from 1 January to 28 January 2020, compared with non&#x02010;ICU patients, 36 severe patients receiving care in the ICU were more likely to have one of the complications such as cardiac injury and arrhythmia.<xref rid="jcmm15364-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> Recently, a systematic review and meta&#x02010;analysis for 1813 COVID&#x02010;19 patients indicated that cardiovascular disease and hypertension were strongly predictive for both severe disease and ICU admission. However, they found that COPD was the most strongly predictive comorbidity for both severe disease (pOR 6.42, 95% CI 2.44&#x02010;16.9) and ICU admission (pOR 17.8, 95% CI 6.56&#x02010;48.2).</p><p>Studies have found that patients with the underlying cardiovascular diseases account for a large proportion of COVID&#x02010;19 patients. A study of the epidemiological and clinical characteristics of 99 COVID&#x02010;19 cases indicated that around 40 per cent had cardiovascular and cerebrovascular diseases.<xref rid="jcmm15364-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> In one study of 138 patients, 58.3% patients with severe symptoms had hypertension.<xref rid="jcmm15364-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> Another study analysed the clinical characteristics of 140 COVID&#x02010;19 patients and found that hypertension, diabetes and cardiovascular and cerebrovascular diseases were the most common underlying diseases in all patients.<xref rid="jcmm15364-bib-0056" ref-type="ref">
<sup>56</sup>
</xref> Therefore, it is important to improve the vigilance of patients with cardiovascular diseases.</p><p>Multiple evidences suggest that SARS&#x02010;CoV&#x02010;2 infects host cells by binding ACE2 receptor widely expressed in the cardiovascular system.<xref rid="jcmm15364-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> Therefore, ACE2&#x02010;related signalling pathway may play a crucial role in cardiac injury. In addition, some scholars consider that there may be an imbalance between Th1 and Th2 responses in COVID&#x02010;19 patients and the resulting cytokine storm could also be another mechanism of cardiac injury.<xref rid="jcmm15364-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> On the other hand, pneumonia caused by SARS&#x02010;CoV&#x02010;2 can lead to respiratory dysfunction and hypoxaemia, which can also bring about cardiomyocyte injury.<xref rid="jcmm15364-bib-0057" ref-type="ref">
<sup>57</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0011"><label>6.2</label><title>COVID&#x02010;19 and tumour</title><p>A study of 1590 COVID&#x02010;19 patients indicated that patients with cancer had a higher risk of COVID&#x02010;19 (1% vs 0.29%) and a higher risk of severe events (a composite endpoint defined as the percentage of patients being admitted to the intensive care unit and requiring invasive ventilation or death) (39% vs 8%) than those without cancer.<xref rid="jcmm15364-bib-0058" ref-type="ref">
<sup>58</sup>
</xref> Current evidence remains insufficient to explain a conclusive association between cancer and COVID&#x02010;19. However, a recent communication in the Lancet refutes this viewpoint, arguing that current evidence is insufficient to explain the conclusive association between cancer and COVID&#x02010;19.<xref rid="jcmm15364-bib-0059" ref-type="ref">
<sup>59</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0012"><label>6.3</label><title>COVID&#x02010;19 and kidney</title><p>Data from a clinical study involving 59 COVID&#x02010;19 patients showed that 19% (11/59) and 27% (16/59) of patients had an elevated level of plasma creatinine and urea nitrogen, respectively. All patients who underwent renal parenchymal CT had abnormal imaging of the kidney, mainly manifesting as low CT values of the renal parenchyma.<xref rid="jcmm15364-bib-0060" ref-type="ref">
<sup>60</sup>
</xref> A study of 1099 COVID&#x02010;19 patients found that the incidence of creatinine &#x0003e;133 micromol/L and acute kidney injury (AKI) were 4.3% and 2.9% in severe patients, respectively, whereas they were only 1% and 0.1%, respectively in non&#x02010;severe patients.<xref rid="jcmm15364-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Data from another study of 710 patients with COVID&#x02010;19 demonstrated that 44% of patients have proteinuria haematuria, 26.9% have haematuria and the prevalence of elevated serum creatinine and blood urea nitrogen were 15.5% and 14.1%, respectively on admission. During the study period, AKI occurred in 3.2% patients. Cox proportional hazard regression confirmed that elevated serum creatinine, elevated urea nitrogen, AKI, proteinuria and haematuria were the independent risk factors for in&#x02010;hospital death.<xref rid="jcmm15364-bib-0061" ref-type="ref">
<sup>61</sup>
</xref>
</p><p>Single&#x02010;cell RNA sequencing data revealed that ACE2 was highly expressed in kidney tubule cells, suggesting that the kidney was at high risk of coronavirus invasion.<xref rid="jcmm15364-bib-0062" ref-type="ref">
<sup>62</sup>
</xref> Moreover, compared with non&#x02010;ICU patients, ICU patients had higher plasma levels of IL&#x02010;2, IL&#x02010;7, IL&#x02010;10, GSCF, IP10, MCP1, MIP1A and TNF&#x02010;&#x003b1;, suggesting that the cytokine storm may be associated with disease severity.<xref rid="jcmm15364-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>
</p></sec></sec><sec id="jcmm15364-sec-0013"><label>7</label><title>DETECTION METHODS</title><sec id="jcmm15364-sec-0014"><label>7.1</label><title>Nucleic acid detection</title><p>Detect SARS&#x02010;CoV&#x02010;2 nucleic acid by real&#x02010;time RT&#x02010;PCR via designing specific SARS&#x02010;CoV&#x02010;2 primers is crucial for COVID&#x02010;19 diagnosis. As above&#x02010;mentioned, SARS&#x02010;CoV&#x02010;2 has 79% and 50% identity with SARS&#x02010;CoV and MERS&#x02010;CoV, respectively<xref rid="jcmm15364-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> whereas 96.3% identity with a bat's coronavirus.<xref rid="jcmm15364-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> Compared the genomic sequences of SARS&#x02010;CoV&#x02010;2 with SARS&#x02010;CoV, regions coding ORF1ab gene, S gene, ORF7b, ORF8 genes and N genes are different.<xref rid="jcmm15364-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> In S gene, SARS&#x02010;CoV&#x02010;2 shows lower GC% and higher AT% than SARS&#x02010;CoV and MERS. As for N gene, SARS&#x02010;CoV&#x02010;2 shows little difference in GC% and AT% compared with SARS&#x02010;CoV and MERS. However, the over&#x02010;biased codons are different. SARS&#x02010;CoV&#x02010;2 has 6 codons, including TTG, CTT, ATT, ACT, GCT and AGA, whereas SARS&#x02010;CoV and MERS show 4 and 5 over&#x02010;biased codons, respectively.<xref rid="jcmm15364-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> Therefore, in consideration of the specific sequence of SARS&#x02010;CoV&#x02010;2, real&#x02010;time RT&#x02010;PCR detection of ORF1ab and N genes is recommended widely. If only one target can be detected due to the restriction of laboratory test kit, at least the ORF1ab region, the most conservative and specific for the new coronavirus, should be detected. Normally, the N gene is recommended as a screening assay and the ORF1ab assay as a confirmatory one. A result of N gene positive/ORF1ab negative should be regarded as indeterminate and the case is recommended to do further test in a WHO reference laboratory.<xref rid="jcmm15364-bib-0065" ref-type="ref">
<sup>65</sup>
</xref> In addition to ORF1ab and N genes, the detection of S gene is also considered by many laboratories.</p><p>Nucleic acid detection technology has the characteristics of early diagnosis, high sensitivity and specificity. &#x02018;Diagnosis and Treatment Guideline of the Novel Coronavirus Pneumonia&#x02019; of China proposed to use fluorescent&#x02010;tagged probe based real&#x02010;time RT&#x02010;PCR to detect SARS&#x02010;CoV&#x02010;2 nucleic acid in respiratory specimens or blood specimens (Table&#x000a0;<xref rid="jcmm15364-tbl-0001" ref-type="table">1</xref>).</p><table-wrap id="jcmm15364-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 1</label><caption><p>The changes of nucleic acid test and serological test in the Diagnosis and Treatment Guideline of COVID&#x02010;19 from version 2 to 7 in China</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Description</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 7 (Mar 4)</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 6 (Feb 18)</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 5 (Feb 4)</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 4 (Jan 27)</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 3 (Jan 23)</th><th align="left" valign="top" rowspan="1" colspan="1">Ver 2 (Jan 18)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Laboratory test</td><td align="left" rowspan="1" colspan="1">
<p>
<italic>1. Aetiological test: nucleic acid test in the specimens of pharyngeal swab, sputum and other lower respiratory tract secretions, blood, faeces by real&#x02010;time RT&#x02010;PCR and NGS.</italic>
</p>
<p>
<italic>Sputum and lower respiratory tract secretions are more accurate;</italic>
</p>
<p>
<italic>2. Serological test: novel coronavirus IgM antibody presents on the 3&#x02010;5&#x000a0;days after COVID&#x02010;19 onset, IgG antibody titre increases 4 times or more in recovery phase compared to acute phase.</italic>
</p>
</td><td align="left" rowspan="1" colspan="1">Nucleic acid test in the specimens of pharyngeal swab, sputum and other lower respiratory tract secretions, blood. <italic>To make sure the accurate result, recommend taking the sputum and secretions from the lower respiration track by tracheal</italic> intubation.</td><td align="left" rowspan="1" colspan="1">Nucleic acid test in the specimens of pharyngeal swab, sputum and other lower respiratory tract secretions, blood and faeces.</td><td align="left" rowspan="1" colspan="1">Nucleic acid test <italic>in the specimens of pharyngeal swab, sputum and other lower respiratory tract secretions, blood.</italic>
</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnosis confirmation</td><td align="left" rowspan="1" colspan="1">
<p>The suspected case, who have one of the following aetiological evidences:</p>
<p>1.Nucleic acid test is positive by real&#x02010;time RT&#x02010;PCR.</p>
<p>2.Have high identity with the known novel coronavirus sequence by NGS.</p>
<p>
<italic>3.Serological test: both the specific IgM and IgG antibody of SARS&#x02010;CoV&#x02010;2 are positive; serological IgG antibody becomes positive or IgG antibody titre increases 4 times or more in recovery phase compared to acute phase</italic>
</p>
</td><td align="left" rowspan="1" colspan="1">
<p>The suspected case, who have one of the following aetiological evidences:</p>
<p>1.Nucleic acid test is positive by real&#x02010;time RT&#x02010;PCR</p>
<p>2.Have high identity with the known novel coronavirus sequence by NGS</p>
</td><td align="left" rowspan="1" colspan="1">
<p>The suspected case, who have one of the following aetiological evidences:</p>
<p>1. Nucleic acid test is positive by real&#x02010;time RT&#x02010;PCR in the respiratory or blood specimens.</p>
<p>2. Have high identity with the known novel coronavirus sequence by NGS in the respiratory or blood specimens</p>
</td><td align="left" rowspan="1" colspan="1">
<p>The suspected case, who have one of the following aetiological evidences:</p>
<p>1. Nucleic acid test is positive by real&#x02010;time RT&#x02010;PCR <italic>in the respiratory or blood specimens.</italic>
</p>
<p>2. Have high identity with the known novel coronavirus sequence by NGS <italic>in the respiratory or blood specimens</italic>
</p>
</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">
<p>Conform to the suspected case standard and have the following:</p>
<p>1.Nucleic acid test is positive by real&#x02010;time RT&#x02010;PCR in the specimens of sputum, pharyngeal swab and lower respiratory tract secretions.</p>
<p>2.Have high identity with the known novel coronavirus sequence by NGS in the specimens of sputum, pharyngeal swab and lower respiratory tract secretions</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Report system</td><td align="left" rowspan="1" colspan="1">
<p>
<italic>The suspected case can be excluded if fitting for the following two conditions: 1. Nucleic acid test is negative in two consecutive times (the interval of sampling time is at least 24&#x000a0;h).</italic>
</p>
<p>
<italic>2. And the specific IgM and IgG antibody of SARS&#x02010;CoV&#x02010;2 are negative after 7&#x02010;d onset</italic>
</p>
</td><td align="left" rowspan="1" colspan="1">The suspected cases should be isolated and tested for nucleic acid of SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">The suspected cases should be isolated and introduced for multidiscipline diagnosis within 2h; If necessary, they should be tested for nucleic acid of SARS&#x02010;CoV&#x02010;2. The suspected case can be excluded if nucleic acid test is negative in two consecutive times (the interval of sampling time is at least 1&#x000a0;day).</td></tr><tr><td align="left" rowspan="1" colspan="1">Release from quarantine</td><td align="left" rowspan="1" colspan="1">
<italic>The out&#x02010;of&#x02010;hospital standard: Nucleic acid test is negative in two consecutive times (the interval of sampling time is at least 24&#x000a0;h) in the specimens of sputum and respiratory tract secretion etc</italic>
</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">The out&#x02010;of&#x02010;hospital standard: Nucleic acid test is negative in two consecutive times (the interval of sampling time is at least 1&#x000a0;d) in the respiratory tract specimens.</td></tr></tbody></table><table-wrap-foot id="jcmm15364-ntgp-0001"><title>Note</title><fn id="jcmm15364-note-0001"><p>The italicized text indicates the increased contents in the guideline compared with the previous version.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Although the viral nucleic acid test is currently the standard method for diagnosis of COVID&#x02010;19, the obvious limitations restrict its extensive use: (a) it usually takes 2&#x02010;3&#x000a0;hours to produce results; (b) real&#x02010;time PCR test requires certified laboratories, expensive equipment and trained technicians for operation; and (c) false negatives exist in real&#x02010;time RT&#x02010;PCR of COVID&#x02010;19.<xref rid="jcmm15364-bib-0066" ref-type="ref">
<sup>66</sup>
</xref> Recently, Abbott ID NOW molecular diagnostic platform technology developed ultra&#x02010;fast DNA or RNA amplification, combined with fluorescence detection system based on the nicking endonuclease amplification reaction (NEAR) technology, which could get bacterial or virus test results within 13&#x000a0;minutes or less (positive results within 5&#x000a0;minutes, negative results within 15&#x000a0;minutes). This technology will substantially speed up the population screening and COVID&#x02010;19 patient identification.<xref rid="jcmm15364-bib-0067" ref-type="ref">
<sup>67</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0015"><label>7.2</label><title>Antibody detection</title><p>Rapid and accurate detection of SARS&#x02010;CoV&#x02010;2&#x02010;specific antibodies in the blood of patients is one of the options for supplemental nucleic acid testing. IgM provides the first line of defence during viral infection, followed by the production of IgG that is important for long&#x02010;term immunity and immunological memory.<xref rid="jcmm15364-bib-0068" ref-type="ref">
<sup>68</sup>
</xref> Moreover, positive IgM antibody often indicates an acute phase of infection while positive IgG antibody indicates late or previous infection. Therefore, we believe that detection of IgM and IgG can also provide information on the time course of virus infection. However, since serological test was gradually established, its diagnostic function was only recognized in &#x02018;Diagnosis and Treatment Guideline of the Novel Coronavirus Pneumonia (Version 7)&#x02019; of China (Table&#x000a0;<xref rid="jcmm15364-tbl-0001" ref-type="table">1</xref>).</p><p>According to a recent study, an increase of viral antibodies can be seen in almost all patients on day 5 after COVID&#x02010;19 onset and the positive rates of IgM and IgG were 81% and 100%, respectively.<xref rid="jcmm15364-bib-0069" ref-type="ref">
<sup>69</sup>
</xref> Therefore, dynamic monitoring of viral IgM or IgG can be considered as a complementary way for nucleic acid detection and could also help to diagnose the COVID&#x02010;19 patient with negative result of nucleic acid test but positive antibody.<xref rid="jcmm15364-bib-0070" ref-type="ref">
<sup>70</sup>
</xref> In addition, antibody test could be crucial to inform public policymakers how many asymptomatic cases have occurred in a population<xref rid="jcmm15364-bib-0071" ref-type="ref">
<sup>71</sup>
</xref> since it is the most convenient and fast approach to identify the asymptomatic cases so far.</p></sec></sec><sec id="jcmm15364-sec-0016"><label>8</label><title>TREATMENT</title><p>Based on the previously therapeutic experience of SARS and MERS, the potential treatments for COVID&#x02010;19 include antiviral drugs, plasma transfusion, vaccines and so on. Given the rapid outbreak and spread of COVID&#x02010;19, repurposing the existing antiviral drugs such as anti&#x02010;HIV drugs, anti&#x02010;HBV and anti&#x02010;HCV drugs is the fast and crucial experimentally therapeutic options and the clinical efficacy of these drugs requires clinical trials to prove.<xref rid="jcmm15364-bib-0072" ref-type="ref">
<sup>72</sup>
</xref> Recently, the WHO director general Tedros Adhanom has announced that WHO will lead clinical trials of four candidate drugs (remdesivir, lopinavir/ritonavir, interferon &#x003b2; and chloroquine) against COVID&#x02010;19 alone or in combination and more than 70 countries have joined WHO's Solidarity Trial to accelerate the search for an effective treatment.<xref rid="jcmm15364-bib-0073" ref-type="ref">
<sup>73</sup>
</xref> So far, a total of 1119 clinical trials have been registered to evaluate therapeutics for COVID&#x02010;19 as of 18 April 2020 (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/">https://www.who.int/blueprint/priority&#x02010;diseases/key&#x02010;action/novel&#x02010;coronavirus/en/</ext-link>). In addition, stem cells are also expected to inhibit the overactivation of immune system, control acute pulmonary inflammation and improve the endogenous reparation for injured tissue,<xref rid="jcmm15364-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>, <xref rid="jcmm15364-bib-0075" ref-type="ref">
<sup>75</sup>
</xref> which will become a new exploration in the treatment of severe COVID&#x02010;19. It also brings new hope for the treatment of novel coronavirus infection&#x02010;related acute respiratory distress syndrome. A clinical trial (NCT04252118) of COVID&#x02010;19 stem cell therapy sponsored by Beijing 302 Hospital is under way.</p><sec id="jcmm15364-sec-0017"><label>8.1</label><title>Antiviral drugs</title><p>Antiviral drugs can be classified as viral protease inhibitors, viral nucleoside analogs and agents that disrupt the interaction mechanism between the virus and the host (Table&#x000a0;<xref rid="jcmm15364-tbl-0002" ref-type="table">2</xref>).</p><table-wrap id="jcmm15364-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 2</label><caption><p>Potential antiviral drugs against COVID&#x02010;19</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Antiviral mechanism</th><th align="left" valign="top" rowspan="1" colspan="1">References</th><th align="left" valign="top" rowspan="1" colspan="1">Evidences</th><th align="left" valign="top" rowspan="1" colspan="1">Therapeutic&#x000a0;effect</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Lopinavir/Ritonavir</td><td align="left" rowspan="3" colspan="1">Viral protease inhibitors</td><td align="left" rowspan="1" colspan="1">Kim et al 2020</td><td align="left" rowspan="1" colspan="1">Clinical case study</td><td align="left" rowspan="1" colspan="1">Did not decease the viral load and have gastrointestinal side effect</td></tr><tr><td align="left" rowspan="1" colspan="1">Cao et al 2020</td><td align="left" rowspan="1" colspan="1">Clinical trial</td><td align="left" rowspan="1" colspan="1">No benefit was observed in hospitalized adult patients with severe Covid&#x02010;19</td></tr><tr><td align="left" rowspan="1" colspan="1">Disulfiram</td><td align="left" rowspan="1" colspan="1">Li and De Clercq 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Has inhibitory activity against SARS and MERS</td></tr><tr><td align="left" rowspan="1" colspan="1">Favipiravir</td><td align="left" rowspan="6" colspan="1">Viral nucleoside analogs</td><td align="left" rowspan="1" colspan="1">Wang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Favipiravir could suppress SARS&#x02010;COV&#x02010;2 infection at a high concentration</td></tr><tr><td align="left" rowspan="4" colspan="1">Remdesivir</td><td align="left" rowspan="1" colspan="1">Holshue et&#x000a0;al 2020</td><td align="left" rowspan="1" colspan="1">Clinical case study</td><td align="left" rowspan="1" colspan="1">Cure a COVID&#x02010;19 patient in the United States by intravenous injection</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Remdesivir could block SARS&#x02010;CoV&#x02010;2 enter Vero E6 cells</td></tr><tr><td align="left" rowspan="1" colspan="1">Gao et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Revealed the possible inhibition mechanism of SARS&#x02010;COV&#x02010;2 RNA polymerase by Remdesivir effector molecules</td></tr><tr><td align="left" rowspan="1" colspan="1">Grein et al 2020</td><td align="left" rowspan="1" colspan="1">Clinical trial</td><td align="left" rowspan="1" colspan="1">Remdesivir is effective in treating severe COVID&#x02010;19.</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribavirin and Galidesivir</td><td align="left" rowspan="1" colspan="1">Li and De Clercq 2020</td><td align="left" rowspan="1" colspan="1">No evidence</td><td align="left" rowspan="1" colspan="1">Have therapeutic effect on patients with SARS and MERS but lacking the evidence for SARS&#x02010;COV&#x02010;2</td></tr><tr><td align="left" rowspan="2" colspan="1">Chloroquine</td><td align="left" rowspan="9" colspan="1">Virus&#x02010;host fusion inhibitors</td><td align="left" rowspan="1" colspan="1">Wang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Suppression of COVID&#x02010;19 pneumonia exacerbation, reduction of symptom duration,</td></tr><tr><td align="left" rowspan="1" colspan="1">Gao et al 2020</td><td align="left" rowspan="1" colspan="1">Clinical trial</td><td align="left" rowspan="1" colspan="1">Have apparent efficacy and acceptable safety against COVID&#x02010;19&#x02010;associated pneumonia in multicentre clinical trials conducted in China.</td></tr><tr><td align="left" rowspan="2" colspan="1">Hydroxychloroquine</td><td align="left" rowspan="1" colspan="1">Wang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Have the same antiviral mechanism with chloroquine</td></tr><tr><td align="left" rowspan="1" colspan="1">Gautret et al 2020</td><td align="left" rowspan="1" colspan="1">Clinical trial</td><td align="left" rowspan="1" colspan="1">Hydroxychloroquine&#x000a0;treatment&#x000a0;is significantly associated with viral load reduction/disappearance in&#x000a0;COVID&#x02010;19&#x000a0;patients and its effect is reinforced by&#x000a0;azithromycin.</td></tr><tr><td align="left" rowspan="1" colspan="1">Arbidol</td><td align="left" rowspan="1" colspan="1">Dong et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Arbidol can effectively inhibit SARS&#x02010;CoV&#x02010;2 infection at a concentration of 10&#x02010;30&#x000a0;&#x000b5;M</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitazoxanide</td><td align="left" rowspan="1" colspan="1">Wang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Have inhibition activity of the SARS&#x02010;COV&#x02010;2</td></tr><tr><td align="left" rowspan="1" colspan="1">IDX&#x02010;184</td><td align="left" rowspan="1" colspan="1">Elfiky 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Have effective against SARS&#x02010;CoV&#x02010;2 strain.</td></tr><tr><td align="left" rowspan="1" colspan="1">Sofosbuvir</td><td align="left" rowspan="1" colspan="1">Elfiky 2020</td><td align="left" rowspan="1" colspan="1">In vitro</td><td align="left" rowspan="1" colspan="1">Tightly combine with SARS&#x02010;CoV&#x02010;2 RdRp for viral clearance</td></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids</td><td align="left" rowspan="1" colspan="1">Zhou and Liu 2020</td><td align="left" rowspan="1" colspan="1">Clinical&#x000a0;experience</td><td align="left" rowspan="1" colspan="1">Low&#x02010;dose corticosteroids may be beneficial for the survival of severe COVID&#x02010;19 patients</td></tr><tr><td align="left" rowspan="1" colspan="1">Baricitinib</td><td align="left" rowspan="1" colspan="1">JAK signalling pathway inhibitor</td><td align="left" rowspan="1" colspan="1">Richardson and Griffin 2020</td><td align="left" rowspan="1" colspan="1">Benevolent AI&#x02010;derived knowledge graph</td><td align="left" rowspan="1" colspan="1">Baricitinib could also abate SARS&#x02010;COV&#x02010;2 virus infectivity</td></tr><tr><td align="left" rowspan="1" colspan="1">Traditional Chinese medicine</td><td align="left" rowspan="1" colspan="1">Antiviral, anti&#x02010;immune/inflammatory and hypoxic reactions</td><td align="left" rowspan="1" colspan="1">Zhang et al 2020</td><td align="left" rowspan="1" colspan="1">In vitro evidence and clinical&#x000a0;experience</td><td align="left" rowspan="1" colspan="1">May also directly inhibit the SARS&#x02010;CoV&#x02010;2</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jcmm15364-sec-0018"><label>8.2</label><title>Viral protease inhibitors</title><p>Lopinavir/ritonavir and disulfiram are the well&#x02010;known viral protease inhibitors and have been shown to be effective against SARS and MERS.<xref rid="jcmm15364-bib-0076" ref-type="ref">
<sup>76</sup>
</xref> Lopinavir/ritonavir were reported to reduce mortality, intubation rate and the use of methylprednisolone when introduced as a treatment of SARS patients in early stage.<xref rid="jcmm15364-bib-0076" ref-type="ref">
<sup>76</sup>
</xref>, <xref rid="jcmm15364-bib-0077" ref-type="ref">
<sup>77</sup>
</xref> A recent study reported two COVID&#x02010;19 cases in South Korea and found that they did not have a significant decrease of the viral load after lopinavir/ritonavir therapy, but experienced gastrointestinal discomfort as a side effect.<xref rid="jcmm15364-bib-0078" ref-type="ref">
<sup>78</sup>
</xref> Recent published result of the first clinical trial for lopinavir/ritonavir indicated that no benefit effect was observed after lopinavir/ritonavir treatment beyond standard care in hospitalized severe COVID&#x02010;19 patients.<xref rid="jcmm15364-bib-0079" ref-type="ref">
<sup>79</sup>
</xref> Disulfiram is a drug for the treatment of alcohol dependence, and studies have confirmed its inhibitory activity against SARS and MERS in cell cultures instead of clinical situation.<xref rid="jcmm15364-bib-0072" ref-type="ref">
<sup>72</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0019"><label>8.3</label><title>Viral nucleoside analogs</title><p>Favipiravir has shown an effective inhibition on Ebola, yellow fever, chikungunya, norovirus and enterovirus by restraining RNA&#x02010;dependent RNA polymerase (RdRp) of RNA viruses.<xref rid="jcmm15364-bib-0080" ref-type="ref">
<sup>80</sup>
</xref> A recent study demonstrated that Favipiravir could suppress SARS&#x02010;CoV&#x02010;2 infection at a high concentration (half&#x02010;maximal effective concentration (EC50)&#x000a0;=&#x000a0;61.88&#x000a0;&#x003bc;mol/L, half&#x02010;cytotoxic concentration (CC50) &#x0003e;400&#x000a0;&#x003bc;mol/L, selectivity index (SI)&#x0003e; 6.46).<xref rid="jcmm15364-bib-0081" ref-type="ref">
<sup>81</sup>
</xref> Remdesivir, approved for HIV infection treatment, has been used to cure a COVID&#x02010;19 patient in the United States by intravenous injection in January 2020.<xref rid="jcmm15364-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> A recent in vitro experiment displayed that remdesivir could block SARS&#x02010;CoV&#x02010;2 to enter Vero E6 cells (ATCC&#x02010;1586) at low concentrations.<xref rid="jcmm15364-bib-0081" ref-type="ref">
<sup>81</sup>
</xref> To determine the clinical efficacy of Remdesivir, two Phase III clinical trials are underway (NCT04252664 and NCT04257656).<xref rid="jcmm15364-bib-0072" ref-type="ref">
<sup>72</sup>
</xref>, <xref rid="jcmm15364-bib-0082" ref-type="ref">
<sup>82</sup>
</xref> The efficacy of nucleotide analogs requires viral RdRps to recognize and successfully incorporate the active form of the inhibitors into the growing RNA strand, which is the possible inhibition mechanism of SARS&#x02010;CoV&#x02010;2 RNA polymerase by remdesivir effector molecules.<xref rid="jcmm15364-bib-0083" ref-type="ref">
<sup>83</sup>
</xref> The latest clinical trial studied the effect of compassionate use of remdesivir in severe COVID&#x02010;19 patients, and clinical improvement was observed in 36 of 53 patients (68%), which indicated that remdesivir was effective in treating severe COVID&#x02010;19.<xref rid="jcmm15364-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0020"><label>8.4</label><title>Virus&#x02010;host fusion inhibitors</title><p>In a study involving more than 100 patients, chloroquine was superior to the control group in suppression of COVID&#x02010;19 pneumonia exacerbation, reduction of symptom duration and delay of viral clearance without severe side effects,<xref rid="jcmm15364-bib-0085" ref-type="ref">
<sup>85</sup>
</xref> but no specific primary or secondary end&#x02010;points. For clinicians accustomed to it, hydroxychloroquine may be preferable for clinical SARS&#x02010;CoV&#x02010;2 treatment. To obtain a better therapeutic effect, a loading dose is recommended prior to a maintenance dose.<xref rid="jcmm15364-bib-0081" ref-type="ref">
<sup>81</sup>
</xref>, <xref rid="jcmm15364-bib-0086" ref-type="ref">
<sup>86</sup>
</xref>, <xref rid="jcmm15364-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> A recent small&#x02010;scale study of COVID&#x02010;19 found that most patients taking chloroquine cleared the novel coronavirus much faster than the control group and adding azithromycin to the medicine could significantly improve the efficiency of eliminating viruses.<xref rid="jcmm15364-bib-0088" ref-type="ref">
<sup>88</sup>
</xref> However, a recent study indicated that chloroquine and hydroxychloroquine could not only be useless in treating COVID&#x02010;19 patients but even harmful. Hence, nevertheless the proved in vitro efficacy, before clinical trials results publication and/or further clarification about COVID&#x02010;19 pathogenesis, clinicians should use it cautionally.<xref rid="jcmm15364-bib-0088" ref-type="ref">
<sup>88</sup>
</xref>, <xref rid="jcmm15364-bib-0089" ref-type="ref">
<sup>89</sup>
</xref>, <xref rid="jcmm15364-bib-0090" ref-type="ref">
<sup>90</sup>
</xref> At present, high quality, adequately powered randomized clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium&#x02010; and long&#x02010;term follow&#x02010;up results and safety data.<xref rid="jcmm15364-bib-0090" ref-type="ref">
<sup>90</sup>
</xref> Arbidol is an anti&#x02010;influenza drug and also used in anti&#x02010;HCV treatment. An in vitro study has revealed that Arbidol could effectively inhibit SARS&#x02010;CoV&#x02010;2 infection at a concentration of 10&#x02010;30&#x000a0;&#x000b5;mol/L, which brought arbidol the potential to treat COVID&#x02010;19 clinically.<xref rid="jcmm15364-bib-0082" ref-type="ref">
<sup>82</sup>
</xref> Nitazoxanide, as an anti&#x02010;diarrhoea medicine, has been shown inhibition activity of the SARS&#x02010;CoV&#x02010;2 in in vitro studies.<xref rid="jcmm15364-bib-0081" ref-type="ref">
<sup>81</sup>
</xref> In the future, combining the molecular mechanisms of these two agents could develop more effective compounds to prevent emerging infections.<xref rid="jcmm15364-bib-0091" ref-type="ref">
<sup>91</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0021"><label>8.5</label><title>Others</title><p>Researches indicated that appropriate use of low&#x02010;dose corticosteroids may be beneficial for the survival of severe COVID&#x02010;19 patients; however, it should strictly comply with the guidelines for recommended COVID&#x02010;19 patients, such as patients with refractory ARDS, sepsis or septic shock.<xref rid="jcmm15364-bib-0091" ref-type="ref">
<sup>91</sup>
</xref>, <xref rid="jcmm15364-bib-0092" ref-type="ref">
<sup>92</sup>
</xref> Based on benevolent AI's proprietary artificial intelligence (AI)&#x02010;derived knowledge graph, baricitinib could also abate SARS&#x02010;CoV&#x02010;2 virus infectivity, virus replication and abnormal host inflammatory response in combination with direct antiviral drugs (lopinavir or ritonavir and remdesivir). This approach could facilitate the subsequent development of anti&#x02010;SARS&#x02010;CoV&#x02010;2 agents.<xref rid="jcmm15364-bib-0093" ref-type="ref">
<sup>93</sup>
</xref> The mechanism of Chinese herbal medicines against COVID&#x02010;19 may include the following process, such as antiviral, immune/inflammatory, hypoxic reactions and so on, and it may also directly inhibit the SARS&#x02010;CoV&#x02010;2.<xref rid="jcmm15364-bib-0094" ref-type="ref">
<sup>94</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0022"><label>8.6</label><title>Convalescent plasma therapy</title><p>Convalescent plasma or immunoglobulins have been shown to improve the survival rate of SARS patients with progressive deterioration.<xref rid="jcmm15364-bib-0095" ref-type="ref">
<sup>95</sup>
</xref> In the pandemic of 2009 influenza A H1N1 (H1N1pdm09) infection, convalescent plasma therapy was found to help to reduce the relative risk of mortality significantly.<xref rid="jcmm15364-bib-0096" ref-type="ref">
<sup>96</sup>
</xref> During the outbreak of Ebola virus disease (EVD) in 2014, the use of convalescent plasma collected from EVD recovery patients was recommended by WHO as one of the treatment modalities.<xref rid="jcmm15364-bib-0097" ref-type="ref">
<sup>97</sup>
</xref> In 2015, the laboratory effect of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection was reported<xref rid="jcmm15364-bib-0098" ref-type="ref">
<sup>98</sup>
</xref> and no severe adverse events occurred among those patients cured by convalescent plasma. An in vivo study also showed that the effects of this antibody were not only limited to free viral clearance and block new infection, but also could accelerate the clearance of infected cells.<xref rid="jcmm15364-bib-0099" ref-type="ref">
<sup>99</sup>
</xref>
</p><p>Currently, it was suggested to collect whole blood or plasma from recovery patients for transfusion to the progressive rapidly, severe and critical COVID&#x02010;19 patients during the SARS&#x02010;COV&#x02010;2 outbreak, but the following principles should be followed: (a) the patient's disease course should not exceed 3&#x000a0;weeks or has viraemia and (b) patients with rapid progression and early severity should be evaluated comprehensively by clinical experts.<xref rid="jcmm15364-bib-0100" ref-type="ref">
<sup>100</sup>
</xref> A recent study showed that conditions of five COVID&#x02010;19 patients have been improved after treating with the plasma of the rehabilitated patients.<xref rid="jcmm15364-bib-0101" ref-type="ref">
<sup>101</sup>
</xref> Two of these antibodies were tested and showed strong anti&#x02010;SARS&#x02010;CoV&#x02010;2 capabilities by the reduction of the binding of SARS&#x02010;CoV&#x02010;2 S protein RBD to human ACE2 with reduction rate of 99.2% and 98.5%, respectively.<xref rid="jcmm15364-bib-0102" ref-type="ref">
<sup>102</sup>
</xref> However, more clinical research should be conducted to prove the safety and effectiveness of convalescent plasma therapy among COVID&#x02010;19 patients.<xref rid="jcmm15364-bib-0103" ref-type="ref">
<sup>103</sup>
</xref>
</p></sec><sec id="jcmm15364-sec-0023"><label>8.7</label><title>Vaccine</title><p>Genomic sequence studies displayed that the spike protein of SARS&#x02010;CoV&#x02010;2 has high identity with that of SARS and MERS, which might indicate the similarity of immune evasion mechanism among SARS&#x02010;CoV&#x02010;2, SARS and MERS.<xref rid="jcmm15364-bib-0104" ref-type="ref">
<sup>104</sup>
</xref>, <xref rid="jcmm15364-bib-0105" ref-type="ref">
<sup>105</sup>
</xref> On the basis of knowledges obtained from SARS and MERS vaccine development, several research groups have announced to start SARS&#x02010;CoV&#x02010;2 vaccine R&#x00026;D immediately after the global outbreak.<xref rid="jcmm15364-bib-0106" ref-type="ref">
<sup>106</sup>
</xref>, <xref rid="jcmm15364-bib-0107" ref-type="ref">
<sup>107</sup>
</xref> As was reported, receptor&#x02010;binding domain in full&#x02010;length spike (S) or S1 was crucial for SARS&#x02010;CoV&#x02010;2 entry into the host cell.<xref rid="jcmm15364-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="jcmm15364-bib-0107" ref-type="ref">
<sup>107</sup>
</xref> This protein is a good vaccine antigen&#x02010;inducing neutralizing antibodies to prevent host cell attachment and against coronavirus infection.<xref rid="jcmm15364-bib-0108" ref-type="ref">
<sup>108</sup>
</xref>, <xref rid="jcmm15364-bib-0109" ref-type="ref">
<sup>109</sup>
</xref> Live attenuated vaccines and inactivated vaccines are based on whole virion.<xref rid="jcmm15364-bib-0037" ref-type="ref">
<sup>37</sup>
</xref>, <xref rid="jcmm15364-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> During Zika virus outbreak, DNA vaccine was the first vaccine candidate that entered clinical trial.<xref rid="jcmm15364-bib-0111" ref-type="ref">
<sup>111</sup>
</xref>, <xref rid="jcmm15364-bib-0112" ref-type="ref">
<sup>112</sup>
</xref>, <xref rid="jcmm15364-bib-0113" ref-type="ref">
<sup>113</sup>
</xref> So far, WHO has listed the detailed information of 86 vaccines under development worldwide, including DNA, RNA, adenoviral vector and recombinant protein vaccine, and six of them have entered into clinical trial (Supplementary Table). To develop SARS&#x02010;CoV&#x02010;2 vaccine successfully, important information related to vaccine development and evaluation should be well defined, including targeted antigen(s), immunization route, related immune protection, animal models, outbreak forecasting and targeted population.<xref rid="jcmm15364-bib-0113" ref-type="ref">
<sup>113</sup>
</xref>, <xref rid="jcmm15364-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> However, the production process and preclinical information of vaccines should be assessed to ensure volunteers&#x02019; safety prior to clinical testing.<xref rid="jcmm15364-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> In a recent interview of the Harvard Office of Technology Development (OTD), researchers suggested that further research and development on a class of molecules called bisphosphonates might turbocharge a vaccine against SARS&#x02010;CoV&#x02010;2 and help bring immunity to huge populations more quickly.<xref rid="jcmm15364-bib-0115" ref-type="ref">
<sup>115</sup>
</xref>
</p></sec></sec><sec sec-type="conclusions" id="jcmm15364-sec-0024"><label>9</label><title>CONCLUSION</title><p>The pandemic of COVID&#x02010;19 has lasted for around 5&#x000a0;months, and so far, the main affected areas have from the original outbreak China to outside regions, especially American and Europe. Fortunately, we already accumulated some knowledge about the pathogen virus, its epidemiological and clinical features, pathogenesis and some effective therapeutic approaches, summarized above, which have contributed to the success against COVID&#x02010;19 and will help human being completely control the epidemic finally.</p></sec><sec sec-type="COI-statement" id="jcmm15364-sec-0026"><title>CONFLICTS OF INTEREST</title><p>The authors declare no conflict of interest.</p></sec><sec id="jcmm15364-sec-0027"><title>AUTHOR CONTRIBUTIONS</title><p>HL and ZL collected, analysed and interpreted the data. HL and J. G. conceived and supervised the study. HL wrote the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jcmm15364-sup-0001"><caption><p>Table S1</p></caption><media xlink:href="JCMM-24-6558-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jcmm15364-sec-0025"><title>ACKNOWLEDGEMENTS</title><p>We appreciate Dr Fujia Liu, Shuangfeng Shi, Kaisheng Lai, Ningyang Hao of BestNovo (Beijing) Medical Technology Co., Ltd. for their technical support. This work was supported by the National Natural Science Foundation of China (81521001, 81870182) and the National Key Basic Research Programme (2016YFC1301204, 2020YFC1316701).</p></ack><sec sec-type="data-availability" id="jcmm15364-sec-0029"><title>DATA AVAILABILITY STATEMENT</title><p>All data, models and code generated or used during the study appear in the submitted article.</p></sec><ref-list content-type="cited-references" id="jcmm15364-bibl-0001"><title>REFERENCES</title><ref id="jcmm15364-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0001">
<string-name>
<surname>Zhu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>8</issue>):<fpage>727</fpage>&#x02010;<lpage>733</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0002">
<string-name>
<surname>Huang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#x02010;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0003">
<string-name>
<surname>Wang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Irwin</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Emergence of SARS&#x02010;like coronavirus poses new challenge in China</article-title>. <source xml:lang="en">J Infect</source>. <year>2020</year>;<volume>80</volume>(<issue>3</issue>):<fpage>350</fpage>&#x02010;<lpage>371</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0004">
<string-name>
<surname>Qin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Dysregulation of immune response in patients with COVID&#x02010;19 in Wuhan, China</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>;<pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id>.</mixed-citation></ref><ref id="jcmm15364-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0005">
<string-name>
<surname>Wu</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Nowcasting and forecasting the potential domestic and international spread of the 2019&#x02010;nCoV outbreak originating in Wuhan, China: a modelling study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10225</issue>):<fpage>689</fpage>&#x02010;<lpage>697</lpage>.<pub-id pub-id-type="pmid">32014114</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0006">
<string-name>
<surname>Chen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>507</fpage>&#x02010;<lpage>513</lpage>.<pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0007">
<string-name>
<surname>Wu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>McGoogan</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID&#x02010;19) Outbreak in China</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>13</issue>):<fpage>1239</fpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0008">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#x02010;infected Pneumonia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>13</issue>):<fpage>1199</fpage>&#x02010;<lpage>1207</lpage>.<pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0009">
<string-name>
<surname>Guan</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>ZY</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0010">
<string-name>
<surname>Verity</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Okell</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Dorigatti</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Estimates of the severity of coronavirus disease 2019: a model&#x02010;based analysis</article-title>. <source xml:lang="en">The Lancet Infect Dis</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30243-7</pub-id>
</mixed-citation></ref><ref id="jcmm15364-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0011">
<string-name>
<surname>Sanche</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Romero&#x02010;Severson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hengartner</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ke</surname>
<given-names>R</given-names>
</string-name>. <article-title>High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2020</year>;<volume>26</volume>(<issue>7</issue>). <pub-id pub-id-type="doi">10.3201/eid2607.200282</pub-id>
</mixed-citation></ref><ref id="jcmm15364-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0012">
<string-name>
<surname>Breban</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Riou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fontanet</surname>
<given-names>A</given-names>
</string-name>. <article-title>Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk</article-title>. <source xml:lang="en">Lancet</source>. <year>2013</year>;<volume>382</volume>(<issue>9893</issue>):<fpage>694</fpage>&#x02010;<lpage>699</lpage>.<pub-id pub-id-type="pmid">23831141</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0013">
<string-name>
<surname>Fang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nie</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Penny</surname>
<given-names>M</given-names>
</string-name>. <article-title>Transmission dynamics of the COVID&#x02010;19 outbreak and effectiveness of government interventions: A data&#x02010;driven analysis</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>6</issue>):<fpage>645</fpage>&#x02010;<lpage>659</lpage>.<pub-id pub-id-type="pmid">32141624</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0014">
<string-name>
<surname>Zou</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ruan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 viral load in upper respiratory specimens of infected patients</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>12</issue>):<fpage>1177</fpage>&#x02010;<lpage>1179</lpage>.<pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0015">
<string-name>
<surname>Lu</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>XF</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>ZF</given-names>
</string-name>. <article-title>2019&#x02010;nCoV transmission through the ocular surface must not be ignored</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10224</issue>):<fpage>e39</fpage>.<pub-id pub-id-type="pmid">32035510</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0016">
<string-name>
<surname>Ong</surname>
<given-names>SWX</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>YK</given-names>
</string-name>, <string-name>
<surname>Chia</surname>
<given-names>PY</given-names>
</string-name>, et al. <article-title>Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2) from a symptomatic patient</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>16</issue>):<fpage>1610</fpage>&#x02010;<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.3227</pub-id>
</mixed-citation></ref><ref id="jcmm15364-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0017">
<string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID&#x02010;19 infection in nine pregnant women: a retrospective review of medical records</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10226</issue>):<fpage>809</fpage>&#x02010;<lpage>815</lpage>.<pub-id pub-id-type="pmid">32151335</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0018">
<string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Possible vertical transmission of SARS&#x02010;CoV&#x02010;2 from an infected mother to her newborn</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0019">
<string-name>
<surname>Wilder&#x02010;Smith</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chiew</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VJ</given-names>
</string-name>. <article-title>Can we contain the COVID&#x02010;19 outbreak with the same measures as for SARS?</article-title>
<source xml:lang="en">Lancet Infect Dis</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0020">
<string-name>
<surname>Huang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>C</given-names>
</string-name>. <article-title>A family cluster of SARS&#x02010;CoV&#x02010;2 infection involving 11 patients in Nanjing</article-title>. <source xml:lang="en">Lancet Infect Dis</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0021">
<string-name>
<surname>Wu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>265</fpage>&#x02010;<lpage>269</lpage>.<pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0022">
<string-name>
<surname>Ceraolo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Giorgi</surname>
<given-names>FM</given-names>
</string-name>. <article-title>Genomic variance of the 2019&#x02010;nCoV coronavirus</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>5</issue>):<fpage>522</fpage>&#x02010;<lpage>528</lpage>.<pub-id pub-id-type="pmid">32027036</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0023">
<string-name>
<surname>Lu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10224</issue>):<fpage>565</fpage>&#x02010;<lpage>574</lpage>.<pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0024">
<string-name>
<surname>Paraskevis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kostaki</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Magiorkinis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Panayiotakopoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sourvinos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tsiodras</surname>
<given-names>S</given-names>
</string-name>. <article-title>Full&#x02010;genome evolutionary analysis of the novel corona virus (2019&#x02010;nCoV) rejects the hypothesis of emergence as a result of a recent recombination event</article-title>. <source xml:lang="en">Infect Genetics Evolut</source>. <year>2020</year>;<volume>79</volume>:<fpage>104212</fpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0025">
<string-name>
<surname>Zhou</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>XL</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XG</given-names>
</string-name>, et al. <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>270</fpage>&#x02010;<lpage>273</lpage>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0026">
<string-name>
<surname>Cyranoski</surname>
<given-names>D</given-names>
</string-name>. <article-title>Mystery deepens over animal source of coronavirus</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7797</issue>):<fpage>18</fpage>&#x02010;<lpage>19</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0027">
<string-name>
<surname>Shi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS&#x02010;coronavirus 2</article-title>. <source xml:lang="en">Science (New York, NY)</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0028">
<string-name>
<surname>Su</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title>. <source xml:lang="en">Trends Microbiol</source>. <year>2016</year>;<volume>24</volume>(<issue>6</issue>):<fpage>490</fpage>&#x02010;<lpage>502</lpage>.<pub-id pub-id-type="pmid">27012512</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0029">
<string-name>
<surname>Cardenas&#x02010;Conejo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Linan&#x02010;Rico</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Rodriguez</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Centeno&#x02010;Leija</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Serrano&#x02010;Posada</surname>
<given-names>H</given-names>
</string-name>. <article-title>An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human&#x02010;pathogenic coronavirus (SARS&#x02010;CoV&#x02010;2)</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>6</issue>):<fpage>688</fpage>&#x02010;<lpage>692</lpage>.<pub-id pub-id-type="pmid">32167166</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0030">
<string-name>
<surname>Benvenuto</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Angeletti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Giovanetti</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Evolutionary analysis of SARS&#x02010;CoV&#x02010;2: how mutation of Non&#x02010;Structural Protein 6 (NSP6) could affect viral autophagy</article-title>. <source xml:lang="en">J Infect</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0031">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>The establishment of reference sequence for SARS&#x02010;CoV&#x02010;2 and variation analysis</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>6</issue>):<fpage>667</fpage>&#x02010;<lpage>674</lpage>.<pub-id pub-id-type="pmid">32167180</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0032">
<string-name>
<surname>Xiaolu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Changcheng</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>
<given-names>L</given-names>
</string-name>. <article-title>On the origin and continuing evolution of SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Natl Sci Rev</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0033">
<string-name>
<surname>Forster</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Renfrew</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>M</given-names>
</string-name>. <article-title>Phylogenetic network analysis of SARS&#x02010;CoV&#x02010;2 genomes</article-title>. <source xml:lang="en">Proc Natl Acad Sci</source>. <year>2020</year>;<fpage>202004999</fpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0034">
<string-name>
<surname>Nhu Thao</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Labroussaa</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ebert</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Rapid reconstruction of SARS&#x02010;CoV&#x02010;2 using a synthetic genomics platform</article-title>. <source xml:lang="en">BioRxiv</source>. <year>2020</year>. published online February 21.</mixed-citation></ref><ref id="jcmm15364-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0035">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>ZJ</given-names>
</string-name>. <article-title>Structure analysis of the receptor binding of 2019&#x02010;nCoV</article-title>. <source xml:lang="en">Biochem Biophys Res Comm</source>. <year>2020</year>;<volume>525</volume>(<issue>1</issue>):<fpage>135</fpage>&#x02010;<lpage>140</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0036">
<string-name>
<surname>Xu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title>. <source xml:lang="en">Sci China Life Sci</source>. <year>2020</year>;<volume>63</volume>(<issue>3</issue>):<fpage>457</fpage>&#x02010;<lpage>460</lpage>.<pub-id pub-id-type="pmid">32009228</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0037">
<string-name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</string-name>, et al. <article-title>Cryo&#x02010;EM structure of the 2019&#x02010;nCoV spike in the prefusion conformation</article-title>. <source xml:lang="en">Science</source>. <year>2020</year>;<volume>367</volume>(<issue>6483</issue>):<fpage>1260</fpage>&#x02010;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0038">
<string-name>
<surname>Yan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</string-name>. <article-title>Structural basis for the recognition of SARS&#x02010;CoV&#x02010;2 by full&#x02010;length human ACE2</article-title>. <source xml:lang="en">Science</source>. <year>2020</year>;<volume>367</volume>(<issue>6485</issue>):<fpage>1444</fpage>&#x02010;<lpage>1448</lpage>.<pub-id pub-id-type="pmid">32132184</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0039">
<string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>W</given-names>
</string-name>. <article-title>Single&#x02010;cell RNA expression profiling of ACE2, thereceptor of SARS&#x02010;CoV&#x02010;2</article-title>. <year>2020</year>: published online January 26.</mixed-citation></ref><ref id="jcmm15364-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0040">
<string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS&#x02010;CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</article-title>. <source xml:lang="en">J Pathol</source>. <year>2004</year>;<volume>203</volume>(<issue>2</issue>):<fpage>622</fpage>&#x02010;<lpage>630</lpage>.<pub-id pub-id-type="pmid">15141376</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0041">
<string-name>
<surname>Liang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus</article-title>. <source xml:lang="en">Gut</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0042">
<string-name>
<surname>Holshue</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>DeBolt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>First Case of 2019 Novel Coronavirus in the United States</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>10</issue>):<fpage>929</fpage>&#x02010;<lpage>936</lpage>.<pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0043"><label>43</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0043">
<string-name>
<surname>Fan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>. <article-title>ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019&#x02010;nCoV Infection</article-title>. <year>2020</year>: published online Feb 13.</mixed-citation></ref><ref id="jcmm15364-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0044">
<string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Compensation of ACE2 function for possible clinical management of 2019&#x02010;nCoV&#x02010;induced acute lung injury</article-title>. <source xml:lang="en">Virol Sin</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0045">
<string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan, China</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>11</issue>):<fpage>1061</fpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0046">
<string-name>
<surname>Xu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Pathological findings of COVID&#x02010;19 associated with acute respiratory distress syndrome</article-title>. <source xml:lang="en">Lancet Respir Med</source>. <year>2020</year>;<volume>8</volume>(<issue>4</issue>):<fpage>420</fpage>&#x02010;<lpage>422</lpage>.<pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0047">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID&#x02010;19 in Wuhan, China: a retrospective cohort study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10229</issue>):<fpage>1054</fpage>&#x02010;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0048">
<string-name>
<surname>Cai</surname>
<given-names>H</given-names>
</string-name>. <article-title>Sex difference and smoking predisposition in patients with COVID&#x02010;19</article-title>. <source xml:lang="en">Lancet Respir Med</source>. <year>2020</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e20</fpage>.<pub-id pub-id-type="pmid">32171067</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0049">
<string-name>
<surname>Wenham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>R</given-names>
</string-name>. <article-title>COVID&#x02010;19: the gendered impacts of the outbreak</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10227</issue>):<fpage>846</fpage>&#x02010;<lpage>848</lpage>.<pub-id pub-id-type="pmid">32151325</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0050">
<string-name>
<surname>Zhao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Relationship between the ABO Blood Group and the COVID&#x02010;19 Susceptibility</article-title>. <year>2020</year>: published online Mar 16.</mixed-citation></ref><ref id="jcmm15364-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0051">
<string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chui</surname>
<given-names>CH</given-names>
</string-name>, et al. <article-title>ABO blood group and susceptibility to severe acute respiratory syndrome</article-title>. <source xml:lang="en">JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>12</issue>):<fpage>1450</fpage>&#x02010;<lpage>1451</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0052">
<string-name>
<surname>Guillon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Clement</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sebille</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Inhibition of the interaction between the SARS&#x02010;CoV spike protein and its cellular receptor by anti&#x02010;histo&#x02010;blood group antibodies</article-title>. <source xml:lang="en">Glycobiology</source>. <year>2008</year>;<volume>18</volume>(<issue>12</issue>):<fpage>1085</fpage>&#x02010;<lpage>1093</lpage>.<pub-id pub-id-type="pmid">18818423</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0053">
<string-name>
<surname>Xu</surname>
<given-names>XW</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>XX</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>XG</given-names>
</string-name>, et al. <article-title>Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS&#x02010;Cov&#x02010;2) outside of Wuhan, China: retrospective case series</article-title>. <source xml:lang="en">BMJ</source>. <year>2020</year>;<volume>368</volume>:<fpage>m606</fpage>.<pub-id pub-id-type="pmid">32075786</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0054">
<string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features</article-title>. <source xml:lang="en">Invest Radiol</source>. <year>2020</year>;<volume>55</volume>(<issue>5</issue>):<fpage>257</fpage>&#x02010;<lpage>261</lpage>.<pub-id pub-id-type="pmid">32091414</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0055">
<string-name>
<surname>Song</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shan</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Emerging 2019 novel coronavirus (2019&#x02010;nCoV) pneumonia</article-title>. <source xml:lang="en">Radiology</source>. <year>2020</year>;<volume>295</volume>(<issue>1</issue>):<fpage>210</fpage>&#x02010;<lpage>217</lpage>.<pub-id pub-id-type="pmid">32027573</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0056">
<string-name>
<surname>Zhang</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>YY</given-names>
</string-name>, et al. <article-title>Clinical characteristics of 140 patients infected with SARS&#x02010;CoV&#x02010;2 in Wuhan, China</article-title>. <source xml:lang="en">Allergy</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0057">
<string-name>
<surname>Zheng</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>X</given-names>
</string-name>. <article-title>COVID&#x02010;19 and the cardiovascular system</article-title>. <source xml:lang="en">Nat Rev Cardiol</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0058">
<string-name>
<surname>Liang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Cancer patients in SARS&#x02010;CoV&#x02010;2 infection: a nationwide analysis in China</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2020</year>;<volume>21</volume>(<issue>3</issue>):<fpage>335</fpage>&#x02010;<lpage>337</lpage>.<pub-id pub-id-type="pmid">32066541</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0059">
<string-name>
<surname>Xia</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>H</given-names>
</string-name>. <article-title>Risk of COVID&#x02010;19 for patients with cancer</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>e180</fpage>.<pub-id pub-id-type="pmid">32142622</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0060">
<string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Caution on Kidney Dysfunctions of COVID&#x02010;19 Patients</article-title>. <source xml:lang="en">SSRN Electr J</source>. <year>2020</year>: published online Feb 12.</mixed-citation></ref><ref id="jcmm15364-bib-0061"><label>61</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0061">
<string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Kidney impairment is associated with in&#x02010;hospital death of COVID&#x02010;19 patients</article-title>. <year>2020</year>: published online Feb 20.</mixed-citation></ref><ref id="jcmm15364-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0062">
<string-name>
<surname>Deng</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>XM</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>Q</given-names>
</string-name>. <article-title>Single&#x02010;cell RNA sequencing data suggest a role for angiotensin&#x02010;converting enzyme 2 in kidney impairment in patients infected with 2019&#x02010;nCoV</article-title>. <source xml:lang="en">Chin Med J (Engl)</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0063">
<string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Systematic comparison of two animal&#x02010;to&#x02010;human transmitted human coronaviruses: SARS&#x02010;CoV&#x02010;2 and SARS&#x02010;CoV</article-title>. <source xml:lang="en">Viruses</source>. <year>2020</year>;<volume>12</volume>(<issue>2</issue>):<fpage>244</fpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0064">
<string-name>
<surname>Kandeel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fayez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Nazawi</surname>
<given-names>M</given-names>
</string-name>. <article-title>From SARS and MERS CoVs to SARS&#x02010;CoV&#x02010;2: moving toward more biased codon usage in viral structural and nonstructural genes</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>6</issue>):<fpage>660</fpage>&#x02010;<lpage>666</lpage>.<pub-id pub-id-type="pmid">32159237</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0065"><label>65</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0065">
<collab collab-type="authors">Health. SoP, Kon. TUoH</collab>
. <article-title>Detection of 2019 novel coronavirus (2019&#x02010;nCoV) in suspected human cases by RT&#x02010;PCR</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0066">
<string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Development and clinical application of a rapid IgM&#x02010;IgG combined antibody test for SARS&#x02010;CoV&#x02010;2 infection diagnosis</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0067">
<string-name>
<surname>Kanwar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Michael</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Doran</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Montgomery</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Selvarangan</surname>
<given-names>R</given-names>
</string-name>. <article-title>Comparison of the ID now influenza A &#x00026; B 2, Cobas Influenza A/B, and Xpert Xpress Flu point&#x02010;of&#x02010;care nucleic acid amplification tests for influenza A/B virus detection in children</article-title>. <source xml:lang="en">J Clin Microbiol</source>. <year>2020</year>;<volume>58</volume>(<issue>3</issue>).</mixed-citation></ref><ref id="jcmm15364-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0068">
<string-name>
<surname>Racine</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Winslow</surname>
<given-names>GM</given-names>
</string-name>. <article-title>IgM in microbial infections: taken for granted?</article-title>
<source xml:lang="en">Immunol Lett</source>. <year>2009</year>;<volume>125</volume>(<issue>2</issue>):<fpage>79</fpage>&#x02010;<lpage>85</lpage>.<pub-id pub-id-type="pmid">19539648</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0069">
<string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Molecular and serological investigation of 2019&#x02010;nCoV infected patients: implication of multiple shedding routes</article-title>. <source xml:lang="en">Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>386</fpage>&#x02010;<lpage>389</lpage>.<pub-id pub-id-type="pmid">32065057</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0070">
<string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>J</given-names>
</string-name>. <article-title>SARS&#x02010;CoV&#x02010;2 lgM/lgG antibody detection confirms the infection after three negative nucleic acid detection</article-title>. <source xml:lang="en">J Cell Mol Med</source>. <year>2020</year>: publish on Apr 2020.</mixed-citation></ref><ref id="jcmm15364-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0071">
<string-name>
<surname>Petherick</surname>
<given-names>A</given-names>
</string-name>. <article-title>Developing antibody tests for SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10230</issue>):<fpage>1101</fpage>&#x02010;<lpage>1102</lpage>.<pub-id pub-id-type="pmid">32247384</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0072">
<string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>De Clercq</surname>
<given-names>E</given-names>
</string-name>. <article-title>Therapeutic options for the 2019 novel coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>149</fpage>&#x02010;<lpage>150</lpage>.<pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0073"><label>73</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0073">
<collab collab-type="authors">World Health Organization</collab>
. <article-title>WHO Director&#x02010;General's opening remarks at the media briefing on COVID&#x02010;19 &#x02010; 8 April 2020</article-title>. WHO <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail">https://www.who.int/dg/speeches/detail</ext-link>. Accessed April 8.</mixed-citation></ref><ref id="jcmm15364-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0074">
<string-name>
<surname>Abreu</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Antunes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Pelosi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Morales</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Rocco</surname>
<given-names>PR</given-names>
</string-name>. <article-title>Mechanisms of cellular therapy in respiratory diseases</article-title>. <source xml:lang="en">Intensive Care Med</source>. <year>2011</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1421</fpage>&#x02010;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">21656291</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0075">
<string-name>
<surname>Silva</surname>
<given-names>LHA</given-names>
</string-name>, <string-name>
<surname>Antunes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Dos Santos</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Cruz</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Rocco</surname>
<given-names>PRM</given-names>
</string-name>. <article-title>Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases</article-title>. <source xml:lang="en">Stem Cell Res Ther</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>45</fpage>.<pub-id pub-id-type="pmid">29482654</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0076">
<string-name>
<surname>Chan</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study</article-title>. <source xml:lang="en">Hong Kong Med J</source>. <year>2003</year>;<volume>9</volume>(<issue>6</issue>):<fpage>399</fpage>&#x02010;<lpage>406</lpage>.<pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0077">
<string-name>
<surname>Chan</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>VT</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>SCW</given-names>
</string-name>, <article-title>COVID&#x02010;19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese&#x02013;Western Medicine for the management of 2019 novel coronavirus disease</article-title>. <source xml:lang="en">Am J Chin Med</source>. <year>2019</year>;<volume>2020</volume>:<fpage>1</fpage>&#x02010;<lpage>26</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0078">
<string-name>
<surname>Kim</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Viral load kinetics of SARS&#x02010;CoV&#x02010;2 infection in first two patients in Korea</article-title>. <source xml:lang="en">J Korean Med Sci</source>. <year>2020</year>;<volume>35</volume>(<issue>7</issue>):<fpage>e86</fpage>.<pub-id pub-id-type="pmid">32080991</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0079">
<string-name>
<surname>Cao</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A trial of lopinavir&#x02010;ritonavir in adults hospitalized with severe covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0080">
<string-name>
<surname>De Clercq</surname>
<given-names>E</given-names>
</string-name>. <article-title>New nucleoside analogues for the treatment of hemorrhagic fever virus infections</article-title>. <source xml:lang="en">Chemistry</source>. <year>2019</year>;<volume>14</volume>(<issue>22</issue>):<fpage>3962</fpage>&#x02010;<lpage>3968</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0081">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x02010;nCoV) in vitro</article-title>. <source xml:lang="en">Cell Res</source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02010;<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0082">
<string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>. <article-title>Discovering drugs to treat coronavirus disease 2019 (COVID&#x02010;19)</article-title>. <source xml:lang="en">Drug Discov Ther</source>. <year>2020</year>;<volume>14</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02010;<lpage>60</lpage>.<pub-id pub-id-type="pmid">32147628</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0083"><label>83</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0083">
<string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Structure of RNA&#x02010;dependent RNA polymerase from 2019&#x02010;nCoV, a major antiviral drug target</article-title>. <year>2020</year>. published online Mar 17.</mixed-citation></ref><ref id="jcmm15364-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0084">
<string-name>
<surname>Grein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ohmagari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Compassionate use of remdesivir for patients with severe Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0085">
<string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>. <article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID&#x02010;19 associated pneumonia in clinical studies</article-title>. <source xml:lang="en">Bioscience Trends</source>. <year>2020</year>;<volume>14</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02010;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32074550</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0086">
<string-name>
<surname>Colson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rolain</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Brouqui</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Raoult</surname>
<given-names>D</given-names>
</string-name>. <article-title>Chloroquine and hydroxychloroquine as available weapons to fight COVID&#x02010;19</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>(<issue>4</issue>):<fpage>105932</fpage>.<pub-id pub-id-type="pmid">32145363</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0087">
<string-name>
<surname>Colson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rolain</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Raoult</surname>
<given-names>D</given-names>
</string-name>. <article-title>Chloroquine for the 2019 novel coronavirus SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>(<issue>3</issue>):<fpage>105923</fpage>.<pub-id pub-id-type="pmid">32070753</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0088">
<string-name>
<surname>Gautret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Parola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID&#x02010;19: results of an open&#x02010;label non&#x02010;randomized clinical trial</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<fpage>105949</fpage>.<pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0089">
<string-name>
<surname>Guastalegname</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vallone</surname>
<given-names>A</given-names>
</string-name>. <article-title>Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID&#x02010;19) treatment?</article-title>
<source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0090">
<string-name>
<surname>Gbinigie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Frie</surname>
<given-names>K</given-names>
</string-name>. <article-title>Should chloroquine and hydroxychloroquine be used to treat COVID&#x02010;19? A rapid review</article-title>. <source xml:lang="en">BJGP Open</source>; <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0091">
<string-name>
<surname>Elfiky</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Anti&#x02010;HCV, nucleotide inhibitors, repurposing against COVID&#x02010;19</article-title>. <source xml:lang="en">Life Sci</source>. <year>2020</year>;<volume>248</volume>:<fpage>117477</fpage>.<pub-id pub-id-type="pmid">32119961</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0092">
<string-name>
<surname>Zhou</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Potential benefits of precise corticosteroids therapy for severe 2019&#x02010;nCoV pneumonia</article-title>. <source xml:lang="en">Signal Transduct Target Ther</source>. <year>2020</year>;<volume>5</volume>:<fpage>18</fpage>.<pub-id pub-id-type="pmid">32296012</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0093">
<string-name>
<surname>Richardson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Baricitinib as potential treatment for 2019&#x02010;nCoV acute respiratory disease</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>e30</fpage>&#x02010;<lpage>e31</lpage>.<pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0094">
<string-name>
<surname>Zhang</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>SQ</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>B</given-names>
</string-name>. <article-title>In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</article-title>. <source xml:lang="en">J Integrative Med</source>. <year>2020</year>;<volume>18</volume>(<issue>2</issue>):<fpage>152</fpage>&#x02010;<lpage>158</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0095">
<string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Soo</surname>
<given-names>YO</given-names>
</string-name>, et al. <article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title>. <source xml:lang="en">Eur J Clin Microbiol Infect Dis</source>. <year>2005</year>;<volume>24</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02010;<lpage>46</lpage>.<pub-id pub-id-type="pmid">15616839</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0096">
<string-name>
<surname>Hung</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>To</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>CK</given-names>
</string-name>, et al. <article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>(<issue>4</issue>):<fpage>447</fpage>&#x02010;<lpage>456</lpage>.<pub-id pub-id-type="pmid">21248066</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0097"><label>97</label><mixed-citation publication-type="book" id="jcmm15364-cit-0097">
<collab collab-type="authors">World Health Organization</collab>
. <source xml:lang="en">Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment During Outbreaks: Interim Guidance for National Health Authorities and Blood Transfusion Services, Version 1.0</source>. <publisher-name>World Health Organization</publisher-name>
<year>2014</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0098">
<string-name>
<surname>Arabi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Balkhy</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hajeer</surname>
<given-names>AH</given-names>
</string-name>, et al. <article-title>Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol</article-title>. <source xml:lang="en">SpringerPlus</source>. <year>2015</year>;<volume>4</volume>:<fpage>709</fpage>.<pub-id pub-id-type="pmid">26618098</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0099">
<string-name>
<surname>Lu</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Murakowski</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Bournazos</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Enhanced clearance of HIV&#x02010;1&#x02010;infected cells by broadly neutralizing antibodies against HIV&#x02010;1 in vivo</article-title>. <source xml:lang="en">Science (New York, NY)</source>. <year>2016</year>;<volume>352</volume>(<issue>6288</issue>):<fpage>1001</fpage>&#x02010;<lpage>1004</lpage>.</mixed-citation></ref><ref id="jcmm15364-bib-0100"><label>100</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0100">
<collab collab-type="authors">China. NHCotPsRo</collab>
. <article-title>Clinical treatment program of convalescent plasma in recovering patients with COVID&#x02010;19 (trial version 2)</article-title>. <year>2020</year>: publish on February.</mixed-citation></ref><ref id="jcmm15364-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0101">
<string-name>
<surname>Shen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Treatment of 5 critically Ill patients WITH COVID&#x02010;19 with convalescent plasma</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0102">
<string-name>
<surname>Ju</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Potent human neutralizing antibodies elicited by SARS&#x02010;CoV&#x02010;2 infection</article-title>. <source xml:lang="en">bioRxiv</source>. <year>2020</year>: Publish on 21 March.</mixed-citation></ref><ref id="jcmm15364-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0103">
<string-name>
<surname>Chang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>. <article-title>Coronavirus disease 2019: coronaviruses and blood safety</article-title>. <source xml:lang="en">Transfus Med Rev</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0104">
<string-name>
<surname>Shanmugaraj</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Siriwattananon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wangkanont</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Phoolcharoen</surname>
<given-names>W</given-names>
</string-name>. <article-title>Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease&#x02010;19 (COVID&#x02010;19)</article-title>. <source xml:lang="en">Asian Pac J Allergy Immunol</source>. <year>2020</year>;<volume>38</volume>(<issue>1</issue>):<fpage>10</fpage>&#x02010;<lpage>18</lpage>.<pub-id pub-id-type="pmid">32134278</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0105">
<string-name>
<surname>Shanmugaraj</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Malla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Phoolcharoen</surname>
<given-names>W</given-names>
</string-name>. <article-title>Emergence of novel coronavirus 2019&#x02010;nCoV: need for rapid vaccine and biologics development</article-title>. <source xml:lang="en">Pathogens</source>. <year>2020</year>;<volume>9</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="jcmm15364-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0106">
<string-name>
<surname>Prompetchara</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ketloy</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Palaga</surname>
<given-names>T</given-names>
</string-name>. <article-title>Immune responses in COVID&#x02010;19 and potential vaccines: lessons learned from SARS and MERS epidemic</article-title>. <source xml:lang="en">Asian Pac J Allergy Immunol</source>. <year>2020</year>;<volume>38</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02010;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32105090</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0107">
<string-name>
<surname>Zheng</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>L</given-names>
</string-name>. <article-title>Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS&#x02010;CoV&#x02010;2 compared to SARS&#x02010;CoV</article-title>. <source xml:lang="en">Cell Mol Immunol</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0108">
<string-name>
<surname>Du</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>S</given-names>
</string-name>. <article-title>The spike protein of SARS&#x02010;CoV&#x02013;a target for vaccine and therapeutic development</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2009</year>;<volume>7</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02010;<lpage>236</lpage>.<pub-id pub-id-type="pmid">19198616</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0109">
<string-name>
<surname>Bhattacharya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Patra</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Development of epitope&#x02010;based peptide vaccine against novel coronavirus 2019 (SARS&#x02010;COV&#x02010;2): Immunoinformatics approach</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>(<issue>6</issue>):<fpage>618</fpage>&#x02010;<lpage>631</lpage>.<pub-id pub-id-type="pmid">32108359</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0110">
<string-name>
<surname>Amanat</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Krammer</surname>
<given-names>F</given-names>
</string-name>. <article-title>SARS&#x02010;CoV&#x02010;2 vaccines: status report</article-title>. <source xml:lang="en">Immunity</source>. <year>2020</year>;<volume>52</volume>(<issue>4</issue>):<fpage>583</fpage>&#x02010;<lpage>589</lpage>.<pub-id pub-id-type="pmid">32259480</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0111">
<string-name>
<surname>Tebas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Muthumani</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Safety and immunogenicity of an Anti&#x02010;Zika Virus DNA vaccine &#x02010; Preliminary Report</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0112"><label>112</label><mixed-citation publication-type="book" id="jcmm15364-cit-0112">S. K, W. P. Editors. <source xml:lang="en">The count of companies developing vaccines for coronavirus rises 2020</source>. <publisher-loc>Redwood</publisher-loc>: <publisher-name>BioCentury</publisher-name>; 2020: publish online Feb 16.</mixed-citation></ref><ref id="jcmm15364-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0113">
<string-name>
<surname>Lucchese</surname>
<given-names>G</given-names>
</string-name>. <article-title>Epitopes for a 2019&#x02010;nCoV vaccine</article-title>. <source xml:lang="en">Cell Mol Immunol</source>. <year>2020</year>.</mixed-citation></ref><ref id="jcmm15364-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="jcmm15364-cit-0114">
<string-name>
<surname>Thomas</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>L'Azou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>NA</given-names>
</string-name>. <article-title>Fast&#x02010;track Zika vaccine development &#x02010; Is it possible?</article-title>
<source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>13</issue>):<fpage>1212</fpage>&#x02010;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">27682032</pub-id></mixed-citation></ref><ref id="jcmm15364-bib-0115"><label>115</label><mixed-citation publication-type="miscellaneous" id="jcmm15364-cit-0115">
<collab collab-type="authors">Medicalxpress</collab>
. <article-title>Vaccine BCG may provide immune boost against coronavirus, herpes, and other viral infections</article-title>. Medicalxpress News. <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://medicalxpress.com.">https://medicalxpress.com.</ext-link> Accessed March 23.</mixed-citation></ref></ref-list></back></article>